InvestorsHub Logo
Followers 971
Posts 383010
Boards Moderated 6
Alias Born 06/24/2011

Re: None

Monday, 01/03/2022 5:23:02 PM

Monday, January 03, 2022 5:23:02 PM

Post# of 468
Summary and updates. SciSparc is a clinical-stage biotechnology company developing cannabinoid-based therapeutics. The company's lead asset, SCI-110(synthetic THC + palmitoylethanolamide (PEA)), is being developed for Tourette syndrome (TS) (phase 2b) and Alzheimer's disease (AD) and agitation (phase 2a). Additionally, SciSparc is developing SCI–210 (CBD + PEA) for status epilepticus and autism spectrum disorder, and SCI-160 (a synthetic CB2 receptor agonist) for pain. The company's achievements in 2021 included preparing to enter midstage studies with SCI-110, publishing key data underpinning the efficacy of its programs, garnering additional IP protection, bolstering the balance sheet with succesful capital markets activities, and uplisting to the Nasdaq exchange.

SPRC
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SPRC News